Resmed tanks overnight on trial failure

The SMH reports that "Medical device maker ResMed has said a major clinical trial that sought to show its sleep therapy products protected heart attack victims, actually put their lives at further risk. The shock clinical trial result will be a major disappointment for ResMed investors who were counting on a positive result to open the door for the company to play a role in the treatment of heart failure, which costs the US government alone $US35 billion each year. (VIEW LINK)


1 stock mentioned

The Livewire Equities feed brings you a range of insights that relate to Australian equities

Expertise

No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.